504 S. Rosa Road
About NeuroPointDxNeuroPointDX is the diagnostics division of Stemina Biomarker Discovery. Stemina is a biotechnology company based in Madison, WI and Cambridge, MA that has developed a robust and reproducible proprietary platform for identifying changes in metabolism (“biomarkers”) utilizing highly sensitive analytical equipment and its proprietary platform technology. The Company’s diagnostics division, NeuroPointDX, identifies biomarkers of neurological disorders in cellular models of disease and human samples. These biomarkers provide greater insight into the pathways that are disrupted in patients with neurological disorders. This information can be translated into clinical diagnostics, individualized treatment recommendations, and new potential therapies.
CEO: Elizabeth Donley
Tweets by NeuroPointDX
8 articles with NeuroPointDx
NeuroPointDX, a division of Stemina Biomarker Discovery, today announced the appointment of two new board members with extensive experience in the development and commercialization of new molecular diagnostic tests. Barbara Handelin, PhD was founding Director of the DNA Diagnostics Lab at Integrated Genetics (acquired by LabCorp @ $925M), and Tony Shuber was Chief Technology Officer and cofounder of Exact Science Corporati
Unique Metabolic Signatures Associated with Autism Spectrum Disorder (ASD) Detect More than 50% of individuals with ASD in Children’s Autism Metabolome Project (CAMP)
New Findings from the CAMP Study, a 1,102 Subject Study of the Metabolism of Children with ASD, Published in Autism Research
Findings from continued analyses of data from 1,100-patient clinical study identify additional metabolic subtypes that may indicate increased risk of ASD diagnosis
NeuroPointDX to Present Precision Medicine Approaches to Diagnosing and Treating Autism at National TACA Autism Conference
Company Will Present New Data from the 1,100 Patient Clinical Study, the Children’s Autism Metabolome Project
Clinician and leader in development of personalized medicine approaches to autism spectrum disorder and other neurodevelopmental conditions
NeuroPointDX Announces Commercialization of First Objective Blood Test to Aid Earlier Diagnosis of Autism Spectrum Disorder
NeuroPointDx, a division of Stemina Biomarker Discovery, today announced the commercial launch of its NPDX AA test, which identifies metabolic subtypes associated with autism spectrum disorder (ASD).
NeuroPointDX Appoints Noted Neurodevelopmental Expert, Marvin Natowicz, M.D., Ph.D. to its Scientific Advisory Board
NeuroPointDX today announced the appointment of Marvin Natowicz, M.D., Ph.D., medical geneticist and clinical pathologist at the Cleveland Clinic and Professor of Pathology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.